Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Update

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) saw a large drop in short interest during the month of December. As of December 31st, there was short interest totaling 13,039 shares, a drop of 21.8% from the December 15th total of 16,674 shares. Based on an average daily volume of 29,226 shares, the short-interest ratio is presently 0.4 days. Approximately 0.4% of the shares of the stock are sold short. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily volume of 29,226 shares, the short-interest ratio is presently 0.4 days.

Hedge Funds Weigh In On Kiora Pharmaceuticals

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Two Sigma Investments LP bought a new stake in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,984 shares of the company’s stock, valued at approximately $33,000. Two Sigma Investments LP owned about 0.33% of Kiora Pharmaceuticals at the end of the most recent reporting period. 76.97% of the stock is currently owned by institutional investors and hedge funds.

Kiora Pharmaceuticals Stock Performance

Shares of KPRX traded down $0.01 during trading hours on Friday, reaching $2.18. The stock had a trading volume of 3,777 shares, compared to its average volume of 27,917. Kiora Pharmaceuticals has a 12 month low of $1.76 and a 12 month high of $4.18. The stock has a market capitalization of $8.02 million, a PE ratio of -1.04 and a beta of -0.89. The company’s 50-day moving average is $2.06 and its two-hundred day moving average is $2.48.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its quarterly earnings results on Friday, November 7th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.73. Equities analysts anticipate that Kiora Pharmaceuticals will post 1.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a research report on Friday, October 31st. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Kiora Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $10.00.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.